HYB-190

N/A

Report date: 2022/08/23 20:00:44

NME

Base Information

Drug NameHYB-190

Drug Alias NamePKAI-AS-190

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense

Mechanisms of ActionProtein kinases inhibitors

TargetsProtein kinases

Therapy Area/IndicationsKidney Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAceragen Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesAceragen Inc

Active IndicationsN/A

Inactive IndicationsKidney Neoplasms

ATC CodeN/A